Cost issues in sequential therapy

Journal of Infection

Volumn 37, Issue SUPPL. 1, 1998, Pages 45-50

  Cooke, J ^a  

^a WITHINGTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BUDGET; CONFERENCE PAPER; DRUG ADMINISTRATION; DRUG MONITORING; HEALTH CARE COST; LENGTH OF STAY; MEDICAL DECISION MAKING; PHARMACOECONOMICS; RISK MANAGEMENT; SIDE EFFECT; TREATMENT FAILURE;

EID: 0031691416     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-4453(98)92743-8     Document Type: Article

References (35)

1. Townsend RJ. Post-marketing drug research and development. Drug Intell Clin Pharm 1987; 21: 134-136.
2. Gladen H. Evaluating the cost-effectiveness of treatment with third-generation cephalosporins. Diagn Microbiol Infect Dis 1992; 15: 99-105.
3. Cooke J, Walley T, Drummond M. Use of health economics for formulary decision making: evidence from the United Kingdom. International Pharmaceutical Abstracts 1996; 33: 2339.
4. Plumridge RJ. Cost comparison of intravenous antibiotic administration. Med J Austral 1990; 153: 516-518.
5. Cousins DH, Lee M, Stanaway M, Neary C. Implementation and evaluation of a centralised IV additive service for antibiotic injections. Pharmaceut J 1989; 242 (Suppl.): HS14-16.
6. Cochrane DMG, Cooke J. Incremental costs of intravenous antibiotic administration in UK teaching hospitals. Pharmaceut J 1993; 251 (Pharmacy Practice Research Suppl.): R18.
7. Eisenberg JM, Koffer H, Glick HA et al. What is the cost of nephrotoxicity associated with aminoglycosides? Intern Med 1987; 107: 900-909.
8. Brushwood DB. Government liable for failure to monitor a patient's serum gentamicin concentration in an Army hospital. Am J Hosp Pharm 1992; 49: 1748-1750.
9. Wilcox MH, Cunniffe JG, Trundle C, Redpath C. Financial burden of hospital-acquired Clostridiwn difficile infection. J Hosp Infect 1996; 34: 23-30.
10. Chan R, Hemeryck L, O'Regan M et al. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open randomised controlled trial Brit Med J 1995; 310: 1360-1362.
11. Paladino JA, Sperry HE, Backes JM et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991; 91: 462-470.
12. Chayakul P, Krisanapan S, Kalnauwakul S. Sequential intravenous/oral ciprofloxacin in the treatment of severe multiresistant gramnegative infections. J Med Assoc Thail 1993; 76: 35-40.
13. Cunha BA. Community-acquired pneumonia. Cost-effective antimicrobial therapy (see comments). Postgrad Med 1996; 99: 109-110, 113-114, 117-119.
14. Davis C. Sequential intravenous/oral ciprofloxacin as an empiric antimicrobial therapy: results of a Canadian multicenter study. Clin Thempeut 1994; 16: 505-521.
15. Feist H. Sequential therapy with i.v. and oral ofloxacin in lower respiratory tract infections: a comparative study. Infection 1991; 19: S380-383.
16. Gaut PL, Carron WC, Ching WT, Meyer RD. Intravenous/oral ciprofloxacin therapy versus intravenous ceftazidime therapy for selected bacterial infections. Am J Med 1989; 87: 169S-175S.
17. Gelfand MS, Simmons BP, Craft RB, Grogan J, Amarshi N. A sequential study of intravenous and oral fleroxacin in the treatment of complicated urinary tract infection. Am J Med 1993; 94: 126S-130S.
18. Gentry LO, Koshdel A. Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure. Am J Med 1989; 87: 132S-135S.
19. Heppt W, Lutz H. Clinical experiences with ofloxacin sequential therapy in chronic ear infections. Europ Arch Otorhinolaryngol 1993; 250 (Suppl.): S19-21.
20. Khan FA, Basir R. Sequential intravenous-oral administration of ciprofloxacin vs ceftazidime in serious bacterial respiratory tract infections. Chest 1989; 96: 528-537.
21. Lau RC, Doyle JJ, Freedman MH, King SM, Richardson SE. Early discharge of pediatric febrile neutropenic cancer patients by substitution of oral for intravenous antibiotics. Fed Hematol Oncol 1994; 11: 417-421.
22. Peacock JEJ, Pegram PS, Weber SF, Leone PA. Prospective, randomized comparison of sequential intravenous followed by oral ciprofloxacin with intravenous ceftazidime in the treatment of serious infections. Am J Med 1989; 87: 185S-190S.
23. Ramirez JA, Srinath L, Ahkee S, Huang A, Raff MJ. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-1276.
24. Santora J et al. Pharmacist intervention program focused on IV. Ranitidine therapy. Am J Hosp Pharm 1990; 47: 1346-1349.
25. Solomkin JS, Reinhart HH, Dellinger EP et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-abdominal Infection Study Group. Ann Surg 1996; 223: 303-315.
26. Trenholme GM, Schmitt BA, Spear J, Gvazdinskas LC. Randomized study of intravenous/oral ciprofloxacin versus ceftazidime in the treatment of hospital and nursing home patients with lowerrespiratory tract infections. Am J Med 1989; 87: 116S-118S.
27. Yoshioka K, Youngs DJ, Keighley MR. A randomised prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intraabdominal infection. Infection 1991; 19: 25-29.
28. Baciewicz AM. Conversion of intravenous ranitidine to oral therapy. Drug Intell Clin Pharm 1991; 25: 251-252.
29. Caceres VM, Stange KC, Kikano GE, Zyzanski SJ. The clinical utility of a day of hospital observation after switching from intravenous to oral antibiotic therapy in the treatment of pyelonephritis (see comments). J Fam Pract 1994; 39: 37-39.
30. Frighetto L, Nickoloff D, Martinusen SM, Mamdani FS, Jewesson PJ. Intravenous-to-oral stepdown program: four years of experience in a large teaching hospital. Ann Pharmacother 1992; 26: 1447-1451.
31. Guay DRP. Sequential antimicrobial therapy. A realistic approach to cost containment? Pharmacoeconomics 1993; 3: 341-344.
32. Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995: 29.
33. Krstenansky PM, Lau J. Technician assistance in switching patients from injectable to oral therapy. Am J Hosp Pharm 1994; 51: 384-386.
34. Malfair SC, Frighetto L, Nickoloff DM, Martinusen SM, Jewesson PJ. Evaluation of the use of cefuroxime and cefuroxime axetil in an intravenous-oral stepdown program. Ann Pharmacother 1996; 30: 337-342.
35. Cooke J, Cairns CJ, Tillotson GS et al Comparative clinical, microbiologic and economic audit of the use of oral ciprofloxacin and parenteral antimicrobials. Ann Pharmacother 1993; 27: 785-789.